✦ LIBER ✦

Efficacy of continuous venovenous hemofiltration with chemotherapy in patients with Burkitt lymphoma and leukemia at high risk of tumor lysis syndrome

✍ Scribed by Kyung A. Choi; Jung Eun Lee; Yoon-Goo Kim; Dae Joong Kim; Kihyun Kim; Young Hyeh Ko; Ha Young Oh; Won Seog Kim; Wooseong Huh

Publisher: Springer
Year: 2008
Tongue: English
Weight: 135 KB
Volume: 88
Category: Article
ISSN: 0939-5555
DOI: 10.1007/s00277-008-0642-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Incidence of tumor lysis syndrome in chi

Incidence of tumor lysis syndrome in children with advanced stage Burkitt's lymphoma/leukemia before and after introduction of prophylactic use of urate oxidase

✍ W. Wössmann; M. Schrappe; U. Meyer; M. Zimmermann; A. Reiter 📂 Article 📅 2003 🏛 Springer 🌐 English ⚖ 192 KB

Risk of secondary myeloid leukemia and m

Risk of secondary myeloid leukemia and myelodysplastic syndrome following standard-dose chemotherapy or high-dose chemotherapy with stem cell support in patients with potentially curable malignancies

✍ C. Kollmannsberger; J. T. Hartmann; L. Kanz; C. Bokemeyer 📂 Article 📅 1998 🏛 Springer-Verlag 🌐 English ⚖ 296 KB

Intravenous itraconazole for prophylaxis

Intravenous itraconazole for prophylaxis of systemic fungal infections in patients with acute myelogenous leukemia and high-risk myelodysplastic syndrome undergoing induction chemotherapy

✍ Gloria N. Mattiuzzi; Hagop Kantarjian; Susan O'Brien; Dimitrios P. Kontoyiannis; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB 👁 1 views

## Abstract ## BACKGROUND Systemic fungal infections remain the leading cause of mortality in patients with newly diagnosed acute myelogenous leukemia (AML) and high‐risk myelodysplastic syndrome (MDS). The objective of the current study was to determine whether intravenous itraconazole (I.V. ITRA

Efficacy and safety of intravenous voric

Efficacy and safety of intravenous voriconazole and intravenous itraconazole for antifungal prophylaxis in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome

✍ Gloria N. Mattiuzzi; Jorge Cortes; Gladys Alvarado; Srdan Verstovsek; Charles Ko 📂 Article 📅 2009 🏛 Springer-Verlag 🌐 English ⚖ 139 KB

Results of intensive chemotherapy in 998

Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: : Predictive prognostic models for outcome

✍ Hagop Kantarjian; Susan O'Brien; Jorge Cortes; Francis Giles; Stefan Faderl; Eli 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 146 KB 👁 1 views

## Abstract ## BACKGROUND Elderly patients (age ≥ 65 years) with acute myeloid leukemia (AML) generally have a poor prognosis. AML‐type therapy results are often derived from studies in younger patients and may not apply to elderly AML. Many investigators and oncologists advocate, at times, only s